FindTrial
Sign In

Preliminary study of mesenchymal stem cells combined with platelet rich plasma injection for refractory tendinopathy

Preliminary study of mesenchymal stem cells combined with platelet rich plasma injection for refractory tendinopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONB-16007725
Enrollment
Unknown
Registered
2016-01-08
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory tendinopathy

Interventions

Intervention Group:mesenchymal stem cells combined with platelet rich plasma injection

Sponsors

First Affiliated Hospital of Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-45 years (18 yr and 45 yr included), male or female; (2) Diagnosed tendinopathy refer to "military training injury diagnostic criteria" and no obvious symptom relief in 3 months after rest and administration of oral non-steroidal anti-inflammatory drugs, topical hormone therapy; (3) Normal heart, lung, liver, kidney function (4) Normal blood coagulation; (5) Unwilling to receive surgery; (6) Agreed to sign the informed consent; (7) Compliance to follow-up process.

Exclusion criteria

Exclusion criteria: (1) Patients of age that does not meet inclusion criteria; (2) Fertility plan within 6 month and pregnancy or breast-feeding women; (3) Non-Indications for MRI Examination; (4) With diseases those could affect the result of the trial.

Design outcomes

Primary

MeasureTime frame
UCLA shoulder score;Mayo elbow performance score;AOFAS ankle - hindfoot score;Adverse effects;—

Countries

China

Contacts

Public ContactTang Kanglai
tangkanglai@hotmail.com+86 13983681188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026